Evidence map›Paper›PMID 37530222›Full record

ArticleBritish journal of pharmacology2024

Ticagrelor inverse agonist activity at the P2Y

Jawad Khalil, Tudor Dimofte, Timothy Roberts, Michael Keith, Kumuthu Amaradasa, Matthew S Hindle, Sukhinder Bancroft, James L Hutchinson, Khalid Naseem, Thomas Johnson and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Biased Allosteric Modulation in GPCR Drug Discovery.Handbook of experimental pharmacology · 2026
    Review
  3. Article
  4. Ticagrelor inverse agonist activity at the P2YBritish journal of pharmacology · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jawad KhalilSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
Tudor DimofteSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
Timothy RobertsSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.ORCID 0000-0002-6680-4816
Michael KeithSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
Kumuthu AmaradasaSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
Matthew S HindleLeeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds, UK.
Sukhinder BancroftSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
James L HutchinsonSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
Khalid NaseemLeeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds, UK.
Thomas JohnsonBristol Medical School, University of Bristol, Bristol, UK.
Stuart J MundellSchool of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.ORCID 0000-0001-7754-3271
University of Bristol · GBUniversity of Leeds · GBBristol Royal Infirmary · GB

Funding

British Heart Foundation PG/17/62/33190British Heart Foundation PG/20/1/34617
6 · The paper itself

Abstract

background and purposeTicagrelor is labelled as a reversible, direct-acting platelet P2Y EXPERIMENTAL APPROACH: Studies were performed in human platelets, with P2Y KEY

resultsInitial studies revealed that a range of P2Y CONCLUSION AND IMPLICATIONS: Ticagrelor binding to P2Y

Indexed as

Acute Coronary SyndromeDiphosphatesAdenosineAdenosine DiphosphateBlood PlateletsDrug Inverse AgonismHumansPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12ThionucleotidesTicagrelorAdenosineAdenosine DiphosphateDiphosphatesmethylthio-ADPPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12ThionucleotidesTicagreloracute coronary syndromeblood plateletsirreversibilityP2Y12 receptorticagrelor

Identifiers

PMID37530222
PMCPMC10953389
OpenAlexW4385476740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.